Jacob Sonenshine is a Reporter at Barron's. He specializes in finance, covering topics such as investment strategies, wealth management, and commodities markets, with a keen interest in stocks and bonds. Jacob's work has been featured in various prominent outlets, including Financial News, Yahoo Finance, and MarketWatch.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jacob Sonenshine's coverage primarily focuses on investment analysis, with an emphasis on the stock market and specific sectors such as bank stocks. He frequently cites data in his articles, indicating a preference for fact-based insights.
Given his focus, Jacob would likely be interested in receiving input from financial analysts or experts who can provide detailed and data-driven perspectives on the stock market trends, particularly within small-cap stocks, S&P 500 movements, and bank stocks' performance.
While he doesn't have a specified geographic focus, Jacob predominantly covers the United States’ financial landscape. Therefore, pitches should align with developments relevant to this region unless they have broader global implications.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jacob Sonenshine
Our Tradeweb Stock Pick Has Struggled. Take Advantage of This Opportunity.
A few sectors have dominated the market this year, and healthcare isn’t one of them. many stocks in the sector look ready to gain.
By: Jacob Sonenshine
The market has fixated on a few sectors this year. It seems to have forgotten about healthcare—making many names in the sector look attractive.
By: Jacob Sonenshine
A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain.
By: Jacob Sonenshine
Evercore analyst Mark Mahaney sees growing signs that internet behemoths will get a return on their soaring capital expenditures.
Everyone is afraid that technology companies are spending too much. But Evercore analyst Mark Mahaney notes that a host of internet companies are
Mark Mahaney sees growing signs that internet behemoths will get a return on their soaring capital expenditures.
Moderna’s stock has doubled this week. There are better buys out there now.
The home to some large pharma companies and many smaller biotechs, have risen over 6% this week. The main catalyst was that Moderna and Merck announced successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.
Biopharmaceutical stocks have emerged winners. Only some will continue to gain.
